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ABSTRACT
Cardiovascular (CV) disease remains the leading
cause of preventable death in the US.
Hyperlipidemia is a major modifiable risk
factor for CV disease, and after numerous
clinical trials have demonstrated that
reductions in low-density lipoprotein (LDL)
cholesterol with statin therapy can prevent
major adverse CV events, statins have emerged
as the drug of choice to lower LDL cholesterol
and reduce CV risk. However, some
statin-treated patients remain at high residual
risk of CV events despite achieving low LDL
cholesterol levels, especially if their triglyceride
(TG) levels are elevated or their high-density
lipoprotein (HDL) cholesterol levels low.
Evidence from genetic and observational
studies has linked elevated TG levels to an
increased risk of CV events. Furthermore, very
high TG levels are associated with acute
pancreatitis. Consequently, several clinical
practice guidelines provide recommendations
for the management and treatment of high and
very high TG levels. This review focuses on the
clinical practice guidelines for the management
of hypertriglyceridemia and the role of
prescription omega-3 fatty acids in preventing
pancreatitis and CV disease in individuals with
high and very high TG levels.
Keywords: Coronary artery disease;
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INTRODUCTION
Cardiovascular (CV) disease is the leading cause
of preventable death in the US [1].
Hyperlipidemia is a major risk factor for CV
disease, and treating elevated cholesterol has
emerged as an important means to prevent CV
events. For the past few decades, the target of
lipid-lowering therapy has been low-density
lipoprotein (LDL) cholesterol, and numerous
large clinical studies in both primary and
secondary prevention settings have
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demonstrated a significant reduction in CV
events in patients treated with statin therapy
[2–4]. A meta-analysis of data from 170,000
patients in 26 randomized studies reported that
for every 38.7 mg/dL (1 mmol/L) reduction in
LDL cholesterol, major vascular events were
reduced by 22% over a 5-year period compared
with placebo [4].
Statins have now become the established
drug of choice to lower LDL cholesterol [5–7].
Despite the benefits seen with statin therapy,
some patients, even if they achieve low LDL
cholesterol levels, remain at high residual CV
risk, especially if levels of triglycerides (TG) are
elevated or high-density lipoprotein (HDL)
cholesterol levels low [8, 9]. In the recent
IMproved Reduction of Outcomes: Vytorin
Efficacy International Trial (IMPROVE-IT),
one-third of patients randomized to a
combination of simvastatin and ezetimibe
suffered a major CV event after a median
follow-up of 6 years. This was despite
achieving a low LDL cholesterol level of
54 mg/dL with combination lipid-lowering
therapy [10]. The high residual CV risk in
patients treated with statin therapy who
achieve low levels of LDL cholesterol may be
due to other risk factors beyond LDL
cholesterol, including elevated TG, low levels
of HDL cholesterol, or the presence of other
non-lipid risk factors such as diabetes,
metabolic syndrome, uncontrolled
hypertension, or cigarette smoking.
Evidence from genetic and observational
studies has linked high TG levels to an increased
risk of CV events. Guidelines from several
national and international medical
organizations provide recommendations for the
managementand treatmentofhighandveryhigh
TG levels, and in addition to lifestyle changes,
these guidelines recommend the use of fibrates,
niacin, or high dose omega-3 fatty acids to lower
TG when the levels are very high [5, 6, 11–14].
However, many physicians are not familiar with
the clinical practice guidelines for the
management of hypertriglyceridemia [15].
Furthermore, citing a lack of effectiveness in CV
outcometrials, theFoodandDrugAdministration
(FDA) recently withdrew approval for
extended-release niacin and certain fenofibric
acid formulations when prescribed in addition
to statins to treat high cholesterol [16]. Because
many patients with high TG are also on statins,
this may lead to less use of these medications and
an increased use of high-dose omega-3 fatty acids
to treat very high TG. For this reason, it is
important for clinicians to be familiar with the
clinicalpractice guidelines for themanagementof
hypertriglyceridemia, and this review focuses on
these clinical guidelines and the role of
prescription omega-3 fatty acids in preventing
pancreatitis and CV disease in individuals with
high and very high TG levels.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Prevalence of hypertriglyceridemia
Hypertriglyceridemia is increasingly common
in the US. An analysis of data from the
National Health and Nutrition Examination
Survey (NHANES) has revealed that the
age-adjusted mean LDL-C has fallen
significantly over the past few decades,
which is most likely related to the increased
use of statins [17]. In contrast, over the same
time period, there was a significant increase in
TG levels [17]. This is likely related to the rise
in obesity also seen during the same period
[18].
According to the most recent guidelines from
the American Heart Association (AHA), TG levels
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are considered normal if they are \150 mg/L,
borderlinehigh if theyare 150–199 mg/dL,high if
they are 200–499 mg/dL, and very high if they are
C500 mg/dL [11]. Data from NHANES show that
from2001 to200632%of theUSadultpopulation
had a TG level C150 mg/dL. Overall, 14% had
borderline-high TG levels, 16% had high TG
levels, and approximately 2% had very high TG
levels [19]. Based on current estimates of the US
adult population, this corresponds to over 34
million individuals with borderline-high TG
levels, over 39 million individuals with high TG
levels, and over 4 million individuals with very
high TG levels. NHANES data also show a
difference in the prevalence of
hypertriglyceridemia (defined as TG levels C150
mg/dL) betweenmen andwomen (29% and 22%,
respectively) and also between age groups [20].
Theprevalenceofhypertriglyceridemia inwomen
increases steadily with age (15% in those aged
20–39 years, 23% in those aged 40–59 years, and
32% in those aged C60 years), while the
prevalence of hypertriglyceridemia in men
increases up to middle age and then appears to
decrease (25% in those aged 20–39 years, 35% in
those aged 40–59 years, and 25% in those aged
C60 years) [20]. There is also a difference in the
prevalence of hypertriglyceridemia among
ethnicities. The most recent NHANES data reveal
thatMexicanAmericanshave ahigher prevalence
of hypertriglyceridemia compared with
non-Hispanic whites or non-Hispanic blacks
[20]. This may be due to genetic reasons. For
example, it has been found that levels of
lipoprotein lipase, an enzyme involved in the
hydrolysis of TG from chylomicrons, and
very-low-density lipoprotein (VLDL) cholesterol
are much higher in African Americans than
whites; this results in lower levels of TG in
African American patients [21]. Conversely,
Asian Indians tend to have high TG levels,
which are thought to be due to a mutation in
theAPOC3 gene, resulting in reduced clearance of
TG from the plasma [22].
Lifestyle and disease states can also
influence the development of
hypertriglyceridemia. The prevalence of
hypertriglyceridemia varies considerably
between individuals who are obese and
overweight and those who are of normal
weight. NHANES data for the period
2009–2012 show that 39% of obese men and
32% of obese women have elevated TG
(C150 mg/dL) compared with 28% of
overweight men and 23% of overweight
women and 15% of normal-weight men and
9% of normal-weight women [20].
Hypertriglyceridemia is also common in
patients with the metabolic syndrome, type 2
diabetes, and renal disease. Approximately 35%
of patients with type 2 diabetes have TG levels
C200 mg/dL [23], and between 40% and 60%
of patients with chronic kidney disease have
TG levels C200 mg/dL [23]. Furthermore,
patients with nephrotic syndrome and those
on peritoneal dialysis have higher TG levels
compared with those patients without
nephrotic syndrome or on hemodialysis [24].
Hypertriglyceridemia and the risk
of pancreatitis
Acute pancreatitis is a well-established
complication of hypertriglyceridemia but may
not be diagnosed in a timely manner as other
conditions can cause similar symptoms. If not
appropriately diagnosed and managed,
pancreatitis can result in repeated
hospitalizations and significant physical,
psychological, and financial burden [25, 26].
Hypertriglyceridemia is the third most
common cause of pancreatitis after alcohol
and gallstones and is found to be the cause of
pancreatitis in up to 4% of cases. It has been
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reported that the incidence of pancreatitis is
increasing, perhaps due to changes in diet and
lifestyle [25]. The risk of acute pancreatitis
increases in a direct relationship to the level of
TG. In a retrospective cohort study, after
adjusting for covariates and excluding
patients with other causes for pancreatitis, the
risk of acute pancreatitis increased by 4% for
every 100 mg/dL increase in TG [27]. Among
patients with severe hypertriglyceridemia, the
risk of pancreatitis is high. In another
retrospective study, 20% of patients with
severe hypertriglyceridemia (defined as TG
levels [1000 mg/dL) experienced at least one
attack of acute pancreatitis [28]. As TG levels
fall rapidly within the first few days of
presentation of acute pancreatitis, it is
important to measure TG levels upon
admission in any patient with acute
pancreatitis to avoid missing
hypertriglyceridemia as the cause. In addition,
mild to moderate hypertriglyceridemia may
occur in pancreatitis due to other causes [29].
In general, acute pancreatitis due to
hypertriglyceridemia typically occurs when
TG levels are[1000 mg/dL [13, 25].
Although the exact role of
hypertriglyceridemia in the etiology of
pancreatitis is not fully known, it is thought that
the associated increase of chylomicrons causes
hyperviscosity, which can lead to ischemia and
acidosis in pancreatic capillaries. This in turn
causes release of pancreatic lipases, increased
lipolysis, and the release of toxic free fatty acids,
which cause cytotoxic injury, inflammation, and
eventually pancreatitis [26, 31].
Hypertriglyceridemia and the risk
of cardiovascular disease
Whether TG causes CV disease has been the
subject of considerable debate. In part, this is
related to the observation that some patients
with very high TG levels are not at risk of CV
disease, whereas other patients with only
mild-to-moderate TG elevations are at
increased CV risk. This paradox can be
explained by the fact that in patients with TG
[1000 mg/dL, the predominant TG
lipoproteins are chylomicrons, which are too
large to penetrate the intimal surface and cause
atherosclerosis [10]. In contrast, in patients with
mild-to-moderate TG elevations, the
predominant TG-rich lipoproteins are VLDL
and intermediate-density lipoprotein (IDL),
whose remnants are small enough to penetrate
the intimal surface and lead to atherosclerosis.
Therefore, it is individuals with
mild-to-moderate TG elevations who are at
particularly high risk of CV disease.
Observational, randomized clinical, and
genetic studies all support the causal
relationship between TG and CV disease. For
example, large population studies such as the
Copenhagen City Heart Study suggest that
increasing levels of non-fasting TG are
associated with increasing risk of myocardial
infarction, ischemic heart disease, ischemic
stroke, and death in adults [32, 33].
Furthermore, the Emerging Risk Factors
Collaboration analyzed more than 300,000
individuals from 68 long-term prospective
studies and found that elevated levels of
fasting and non-fasting TG were associated
with an increased risk of coronary heart
disease after adjusting for non-lipid risk factors
[34]. This risk was attenuated after adjusting for
non-HDL cholesterol levels, which suggests that
it is the cholesterol within TG-rich remnant
lipoproteins that is the cause of coronary heart
disease rather than the increase in TG
themselves. Other studies have shown that the
CV risk associated with TG is attenuated when
adjusting for HDL cholesterol [35]. Low levels of
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HDL cholesterol are commonly associated with
hypertriglyceridemia. TG levels can vary widely
on a daily basis, while levels of HDL cholesterol
are less variable; therefore, low HDL cholesterol
may be a marker for the presence of TG-rich
remnant lipoproteins, which may explain why
it is more strongly associated with CV disease
than TG [36].
Despite the increasing use of statins, and the
subsequent reduction in LDL cholesterol, some
statin-treated patients remain at risk of CV
disease in part because of elevated TG levels.
In a pooled analysis of two large clinical
outcomes studies with statin therapy, the
Treating to New Targets (TNT) and
Incremental Decrease in End Points through
Aggressive Lipid Lowering (IDEAL) studies, the
CV risk was higher in patients with
on-treatment TG C150 mg/dL than in those
with TG\150 mg/dL [8]. After adjusting for age
and sex, the risk of a CV event increased across
the quintiles of TG. Patients in the highest
quintile of TG levels had a 63% higher CV event
rate than those in the lowest quintile, despite
having achieved low LDL cholesterol levels with
statin therapy. The average LDL cholesterol
level in IDEAL was 91 mg/dL and 87 mg/dL in
TNT. In an analysis of patients with acute
coronary syndromes from the dal-OUTCOMES
study and the atorvastatin arm of the
Myocardial Ischemia Reduction with Acute
Cholesterol Lowering (MIRACL) study, it was
found that the higher the on-treatment TG
level, the higher the CV risk [37]. The long-term
CV risk was two-fold higher in patients with TG
[175 mg/dL compared with those with TG
\100 mg/dL. The increased CV risk associated
with elevated levels of TG occurred on the
background of effective statin therapy. The
median LDL cholesterol level achieved in the
dal-OUTCOMES study was 73 mg/dL, and
approximately 97% of patients were taking a
statin. The risk associated with increasing TG
levels remained significant and was not
attenuated after adjusting for other risk
factors, including HDL and LDL cholesterol
levels.
Mendelian randomization studies have
provided further evidence linking TG and CV
disease. In a large Mendelian randomization
study, heterozygotes for a single APOA5
genetic variant had a 16% higher mean TG
level, and homozygotes had a 33% higher
mean TG level than non-carriers [38]. The risk
of coronary heart disease increased in a
dose-dependent manner, with an
approximately 18% higher CV risk for each
variant allele inherited. In another large
Mendelian randomization study, a total of
73,513 subjects from Copenhagen were
genotyped and 15 genetic variants were
selected that affected non-fasting remnant
cholesterol, HDL cholesterol, or both [39].
The term remnant cholesterol refers to the
cholesterol carried on TG-rich lipoproteins
including chylomicrons remnants, VLDL, and
intermediate-density lipoproteins (IDL) and in
this study was calculated by subtracting HDL
and LDL cholesterol from total cholesterol. A
non-fasting remnant cholesterol increase of
39 mg/dL was associated with a 2.8-times
increased risk for ischemic heart disease,
independent of low levels of HDL
cholesterol. Genome-wide association studies
have also provided evidence of the causal
relationship between TG and CV disease. Two
studies showed that loss-of-function mutations
in APOC3 were associated with lower levels of
TG and a reduced risk of ischemic heart and
vascular disease [40, 41]. Taken together, these
genetic, clinical, and population studies
support a strong causal relationship between
high concentrations of TG-rich lipoproteins or
remnant cholesterol and CV disease.
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TGs are predominantly carried in the
circulation by chylomicrons and VLDL
particles. These lipoprotein particles undergo
remodeling via the actions of lipoprotein lipase
and other lipases, which leads to the formation
of remnant particles, often termed TG-rich
remnant lipoproteins. Remnant particles
include chylomicron remnants as well as
VLDL and IDL particles. Non-HDL cholesterol
is a measure of the cholesterol content of these
TG-rich remnant lipoproteins and is defined as
total cholesterol minus HDL cholesterol. When
TG levels are C1000 mg/dL, the predominant
particles carrying TG are large chylomicrons.
These particles are too large to penetrate the
intima of the arterial wall and so are not usually
associated with an increased risk of CV disease.
However, these patients are at risk of acute
pancreatitis. In contrast, in patients with
elevated TG levels \1000 mg/dL, the
predominant particle in the circulation is
VLDL. Incomplete lipolysis of VLDL leads to
the formation of remnant particles, which are
small enough to penetrate the intima, leading
to injury, inflammation, and atherosclerosis.
These TG-rich remnant particles, in addition to
carrying TG, carry a large amount of
cholesterol. Unlike cholesterol, most cells
easily degrade TG, and it is the cholesterol in
these particles that is the likely cause of
atherosclerosis. Because these particles carry
more cholesterol than LDL particles, they are
particularly atherogenic. Once trapped within
the intimal surface, TG-rich remnants can be
taken up directly by macrophages, leading to
the formation of foam cells (Fig. 1) [36]. In
addition to the direct effects that TG-rich
remnants have on the arterial intima, there
may be other indirect mechanisms by which
these remnant particles cause atherosclerosis
[37].
Treating hypertriglyceridemia
The AHA, National Lipid Association (NLA),
Endocrine Society (ES), and the ESC (European
Society of Cardiology) and EAS (European
Atherosclerosis Society) have all developed
guidelines for the classification and treatment
of hypertriglyceridemia (Table 1) [5, 6, 11–14].
Although the most recent ACC/AHA cholesterol
guidelines do not provide specific
recommendations for the treatment of
hypertriglyceridemia, they do recommend
following the earlier published AHA scientific
statement on the treatment of
hypertriglyceridemia [7]. The AHA [11] has
defined an optimal fasting TG level as
\100 mg/dL. For individuals with fasting TG
levels of \150 mg/dL or a nonfasting level of
B200 mg/dL, no further testing for
hypertriglyceridemia is indicated, although
lifestyle changes may be of value based on an
individuals CV risk. If a nonfasting TG level is
C200 mg/dL, then a fasting lipid panel is
recommended. The cornerstone for the
treatment of hypertriglyceridemia is lifestyle
intervention with diet and exercise. However,
pharmacologic therapy to lower TG may be
considered based on an individuals CV risk and
how high the level of TG are.
Treating very high TG levels (‡500 mg/dL)
The AHA [11] and NLA [5] define very high TG
as C500 mg/dL, whereas the ES [12] uses a
different nomenclature and defines severe
hypertriglyceridemia as TG levels of
1000–1999 mg/dL and very severe
hypertriglyceridemia as C2000 mg/dL. The EAS
[13] defines mild to moderate
hypertriglyceridemia as[150 and\880 mg/dL
(10 nmol/L). Severe hypertriglyceridemia is
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defined as C880 mg/dL. In an individual with
very high TG levels, the system to remove VLDL
from the circulation is saturated, such that
much more severe hypertriglyceridemia can
develop with dietary indiscretion or when
other metabolic disorders develop in
individuals with very high TG levels [41]. For
this reason, both the AHA [11] and NLA [5] have
chosen a lower threshold than the ES [12] or the
ESC and EAS [13, 14] at which to target TG to
Fig. 1 Mechanisms by which TG and remnant cholesterol
may lead to atherosclerosis [35]. TG-rich remnant
lipoproteins, similar to LDL cholesterol, are small enough
to enter the arterial intima where they can be directly
taken up by macrophages, leading to local injury,
inﬂammation, and atherosclerosis. Chylomicrons are
too large to enter the arterial intima and hence do not
usually lead to atherosclerosis. FFA free fatty acid, LDL
low-density lipoprotein, LPL lipoprotein lipase
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prevent pancreatitis. Although there are some
differences among the guidelines as to what
defines very high or severe
hypertriglyceridemia, there is consensus that
the main goal of treating very high TG levels is
to reduce the risk of pancreatitis. In individuals
with very high TG levels, an evaluation should
be undertaken as to the cause of the very high
TG levels and intense lifestyle interventions
should be undertaken with strict
recommendations to limit dietary fat and
abstain from alcohol. The NLA in its Part 2
Recommendations for Patient Centered
Management of Dyslipidemia recommend
limiting fat to 10–15% of calories, 30–60 min
of exercise most days, and avoidance of alcohol,
added sugar, and refined carbohydrates [6].
Once the TGs fall to \500 mg/dL, dietary fat
can be gradually advanced as tolerated. In
addition to lifestyle intervention, both the
AHA [11] and the NLA [5, 6] recommend
TG-lowering medications when the TG levels
are C500 mg/dL. The NLA recommends that
when TG levels are C1000 mg/dL an agent that
primarily lowers TG such as prescription
omega-3 fatty acids and fibrates be used as
first-line therapy; however, in patients with TG
levels of 500–999 mg/dL, if there is no history of
pancreatitis a statin may also be considered as
first-line therapy. This is because statins have a
modest effect on lowering TG. Ezetimibe has
only a limited TG-lowering effect, lowering TG
by about 5–10%, whereas bile acid sequestrants
can increase TG levels [5, 10] and should not be
used in patients with severe
hypertriglyceridemia. Often in patients with
very high TG levels, combination TG-lowering
therapy is required. The ES [12] recommends
drug therapy along with lifestyle intervention
to reduce the risk of pancreatitis when the TG
levels are[1000 mg/dL and recommends that a
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individuals with severe hypertriglyceridemia.
The recent ESC and EAS guidelines [14]
recommend, along with dietary intervention,
pharmacological therapy to prevent pancreatitis
when the TG levels are severely elevated
(C880 mg/dL). Similar to the ES
recommendations [12], a fibrate is the drug of
first choice; however, the ESC and EAS also
recommend that in patients with severe
hypertriglyceridemia, high-dose omega-3 fatty
acids or niacin be initiated along with fibrate
therapy [14].
The goal of therapy is to lower the TG to
levels at which the risk of pancreatitis is low.
The AHA and the ESC and EAS do not
recommend a specific target for TG reduction,
while the ES recommends a treatment goal for
TG levels of \1000 mg/dL and the NLA a
treatment goal of\500 mg/dL. However, there
may be additional clinical benefit in lowering
TG closer to the normal range. In a large
retrospective cohort study of 41,210 adults
with very high TG levels (C500 mg/dL), the
larger the TG reduction, the greater the clinical
benefit. In an average follow-up of
approximately 90 days, 79% of patients
experienced a reduction in their TG levels to
\500 mg/dL and 25% achieved TG levels
\200 mg/dL. The use of TG-lowering therapy
was significantly greater in those patients who
achieved TG levels \200 mg/dL compared to
those with higher TG levels in follow-up. Those
patients who had a follow-up TG level of
\200 mg/dL demonstrated the greatest
reduction in the risk of pancreatitis [44]. This
study suggests that in patients with very high
TG levels the greatest clinical benefit occurs
when the TG levels are lowered to an almost
normal level. However, it should be noted that
no randomized prospective clinical trial to date
has evaluated the benefit of treating very high
TG levels with TG-lowering therapy to reduce
the risk of pancreatitis nor identified the
optimal level of TG reduction associated with
a low risk of pancreatitis.
Patients with very high TG levels may be at
increased CV risk even though their TG levels
are lowered to a level at which they are no
longer at risk for pancreatitis. The decision for
additional lipid-lowering therapy should be
based on current guidelines and an
individual’s CV risk. The 2013 ACC/AHA
cholesterol guidelines identified four patient
groups who would benefit from moderate to
high dose statin therapy [7]. If an individual
with very high TG falls into one of these patient
groups, once the TG are lowered consideration
should be given to adding a statin to their
TG-lowering therapy. Although most
TG-lowering drugs are well tolerated in
combination with a statin, it should be noted
that gemfibrozil is contraindicated in
combination with statins because of the
increased risk of serious myopathy [5, 11]. If
the TG levels fall to a normal or borderline level
with lifestyle changes and combination
lipid-lowering therapy, consideration may be
given to discontinuing the non-statin
TG-lowering medication. However, the TG
levels will need to be monitored closely for
any rise in the TG levels. Although the ACC/
AHA guidelines no longer recommend target
lipid goals, both the NLA [5], the ES [12], and
the ESC and EAS [14] advocate for the use of
target lipid goals in clinical practice. Based on
an individual’s CV risk the NLA recommends
both non-HDL and LDL cholesterol be the
primary targets of therapy, while the ESC and
EAS recommend LDL cholesterol as the primary
target of therapy and non-HDL cholesterol and
apoliprotein B levels as secondary targets. The
ES recommends for individuals with severe
hypertriglyceridemia the treatment goal be
non-HDL cholesterol. Non-HDL cholesterol is
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total cholesterol minus HDL cholesterol and
takes into account not only the cholesterol
carried by LDL, but also IDL, VLDL, and VLDL
remnants. Epidemiologic studies have shown
that non-HDL cholesterol is a better predictor of
CV risk than is LDL cholesterol [45], especially
when the on-treatment values are discordant
[46].
Treating high TG levels (200–499 mg/dL)
Unlike very high TG levels, individuals with high
TG levels (200–499 mg/dL) are not at risk for
pancreatitisbutmaybeat risk forCVdisease.Allof
the guidelines recommend lifestyle changes as
first-line therapy for individuals with high TG
levels including diet, weight loss, reduced alcohol
consumption, and increased physical activity
[5, 6, 11–14]. In contrast to the strict restriction
of dietary fat for individuals with very high TG
levels, individuals with high TG levels should be
recommended a diet low in sugar and refined
carbohydrates. Even small changes to a patient’s
diet can have clinically significant effects on TG
levels. Eliminating trans fatty acids, such as those
found in margarine and bakery products,
restricting sugar, refined carbohydrates, and
alcohol, and increasing unsaturated fats and
marine-based omega-3 products have the
potential to reduce TG levels by around 10–20%
[5, 6, 11]. Weight loss can also have a beneficial
effect on all lipids and lipoproteins. A 20%
decrease in TG can be achieved with a 5–10%
reduction in bodyweight [5, 6, 11]. An increase in
physical activity can aid weight loss and reduce
TG, especially in those who exercise at least
moderately [11]. It is important to note that
reductions in TG through changes in diet and
lifestyle are additive, so it is possible
for individuals to achieve significant reductions
in TG if all recommendations are implemented
[10].
Although the epidemiologic evidence is
strong that high TG levels are independently
associated with CV risk, there are no completed
outcome studies that specifically targeted
individuals with high levels of TG. For this
reason, other than lifestyle changes there are no
formal guidelines to treat individuals with TG
levels of 200–499 mg/dL with lipid-lowering
therapy. However, based on current guidelines
many patients with high levels of TG will fall
into a CV risk category that would warrant
consideration for statin therapy. Although no
statin trial has specifically looked at patients
with high TG, secondary analyses from several
of the major statin trials have shown a
consistent benefit in subsets of patients with
high TG alone or in combination with low HDL
cholesterol. For example, in the Scandinavian
Simvastatin Survival Study (4S), simvastatin
reduced major CV events by 45% compared
with placebo. Furthermore, CV events were
reduced more in patients with high TG and
low HDL-C levels than in patients with isolated
elevations in LDL cholesterol [47]. Secondary
analyses from trials of other lipid-lowering
drugs have shown similar results. In both the
Helsinki Heart Study (HHS) [48] and the
Veterans Affairs HDL Intervention Trial
(VA-HIT) [49], gemfibrozil significantly
reduced the incidence of CV events compared
with placebo in the overall study population. In
both studies, the subgroups of patients with
elevated TG levels showed greater CV risk
reduction than the general study population
[50, 51]. In contrast to these studies, there was
no improvement in CV outcomes in two large
CV disease prevention studies in patients with
diabetes: the Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) trial, [52]
which compared fenofibrate with placebo, and
the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial [53], which compared
310 Adv Ther (2017) 34:300–323
fenofibrate plus simvastatin with simvastatin
alone. However, in patients with baseline TG
[204 mg/dL and low HDL cholesterol, a 27%
risk reduction (p = 0.005) was seen in FIELD
[54], and a 31% reduction in CV events
(p = 0.057) was seen in ACCORD [53]. As with
the fenofibrate studies, in the Atherothrombosis
Intervention in Metabolic syndrome with low
HDL/high triglycerides: Impact on Global
Health outcomes (AIM-HIGH) study,
extended-release niacin in combination with a
statin failed to reduce CV events in high-risk
men and women [55]. In the Heart Protection
Study 2–Treatment of HDL to Reduce the
Incidence of Vascular Events (HPS2-THRIVE)
trial extended-release niacin and laropiprant
when added to a statin did not significantly
reduce major CV events in patients with
atherosclerotic vascular disease, but increased
the risk of bleeding, infection, worsening
diabetic control, and other adverse events
associated with the gastrointestinal and
musculoskeletal systems [56]. However, in the
subgroup of patients in AIM-HIGH with
baseline TG[200 mg/dL and HDL cholesterol
\32 mg/dL, a significant reduction in CV events
was demonstrated [57]. With regard to omega-3
fatty acids, the Japanese Eicosapentaenoic Acid
(EPA) Lipid Intervention Study (JELIS)
demonstrated a 19% reduction in major CV
events in the EPA group compared with the
statin-alone group [58]; however, in patients
with elevated TG and low HDL cholesterol at
baseline an even greater CV risk reduction was
seen. EPA treatment lowered the risk of a major
cardiac event by 53% in those patients with
elevated TG and low HDL cholesterol compared
to the statin-alone group [59]. Taken together,
the evidence from these subanalyses in patients
with elevated TG suggests that lowering TG may
lead to favorable CV outcomes.
Two large-scale outcomes studies are
currently investigating the effect of
prescription omega-3 fatty acids in
combination with statins on CV events in
high-risk patients with high TG levels. The
Reduction of Cardiovascular Events with
EPA-Intervention Trial (REDUCE-IT;
NCT01492361) is assessing the effect of
icosapent ethyl (IPE) (Vascepa) in
statin-treated patients with or at high risk for
CV disease who have high TG levels
(C200 mg/dL). The endpoint is a composite
of CV death, myocardial infarction, stroke,
coronary revascularization, and hospitalization
for unstable angina and is expected to
complete in December 2017 [60]. The STatin
Residual risk reduction with EpaNova in hiGh
cardiovascular risk paTients with
Hypertriglyceridemia (STRENGTH;
NCT02104817) study is evaluating the effect
of omega-3 carboxylic acids (OM3CA)
(Epanova) in statin-treated patients at high
risk for CV disease with TG levels C180 mg/
dL. The endpoint is the first occurrence of a
major adverse coronary event, including CV
death, nonfatal myocardial infarction,
nonfatal stroke, coronary revascularization, or
hospitalization for unstable angina and is
expected to complete in June 2019 [61].
As we await the results of these trials,
individuals with high TG levels between 200
and 499 mg/dL should be treated with lifestyle
intervention and should be considered for
statin therapy based on current cholesterol
guidelines and their CV risk. The NLA
recommends that for patients whose TG levels
remain high despite statin therapy, the clinician
should consider a TG-lowering drug such as a
fibrate or high-dose omega-3 fatty acids based
on their CV risk and their non-HDL cholesterol
goal [5, 6].
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Treating borderline high TG levels
(150–199 mg/dL)
For individuals with borderline high TG levels,
pharmacotherapy is not recommended to lower
TG but rather therapeutic lifestyle changes
remain the focus of treatment to help lower
TG levels [5, 11]. As with patients with high TG
levels a diet low in sugar and refined
carbohydrates, weight loss, and exercise will
likely bring the TG levels to the normal or
optimal range.
The use of omega-3 fatty acid preparations
to lower TG levels
Omega-3 fatty acids are available in the form of
prescription drugs or non-prescription dietary
supplements and lower fasting and postprandial
TG levels in a dose-dependent manner [11].
Prescription omega-3 fatty acids are more
potent and more effective than
non-prescription supplements and are the
preferred choice for lowering very high TG
[62]. The prescription omega-3 fatty acids that
are currently approved in the US to treat
patients with very high TG levels (C500 mg/
dL) are primarily available as EPA alone or in
combination with docosahexaenoic acid (DHA)
[63–66].
The mechanism by which omega-3 fatty
acids lower TG is multifactorial and is thought
to involve decreased hepatic lipogenesis,
increased b-oxidation of fatty acids, inhibition
of key enzymes involved in hepatic TG
synthesis, and increased expression of
lipoprotein lipase [67–72]. Together with their
TG-lowering effects, omega-3 fatty acids are also
thought to have anti-arrhythmic [73],
anti-thrombotic, anti-atherosclerotic [74], and
anti-inflammatory effects [75], as well as
promoting improvements in endothelial
function [76] and lowering blood pressure
[77]. All of these effects may contribute to the
CV benefits associated with omega-3 fatty acids.
There are currently three prescription
omega-3 fatty acid formulations approved in
the US for the management of
hypertriglyceridemia: (1) a mixture of long
chain omega-3 fatty acid ethyl esters (OM3EE),
primarily EPA, and DHA (Lovaza, OmtrygTM,
and some generics). Each 1-g capsule of OM3EE
contains 465 mg of EPA and 375 mg of DHA;
[64, 65], (2) IPE (EPA ethyl esters) (Vascepa),
with each 1-g capsule containing 1 g of IPE;
[63], and (3) OM3CA, a mixture of long-chain
omega-3 fatty acids in free fatty acid form,
primarily EPA, DHA, and docosapentaenoic acid
(Epanova). Each 1-g capsule contains 75% EPA
plus DHA [66]. DHA and EPA, the main
components of omega-3 fatty acids, have
different effects on LDL cholesterol, HDL
cholesterol, and TG. A 2011 meta-analysis of
studies directly comparing the effects of the
DHA and EPA components found that there was
a greater reduction in TG, at the expense of a
greater increase in LDL cholesterol with DHA
compared with EPA. In addition, DHA increased
HDL cholesterol but EPA did not when
compared with placebo [78]. Omega-3 fatty
acids also reduce apolipoprotein C3, a key
contributor to the development of
hypertriglyceridemia and the progression of
atherosclerosis and CV disease [79].
Effects of omega-3 fatty acids on TG, LDL
cholesterol, and other lipoproteins
Table 2 summarizes data from clinical studies
investigating the effect of each of the three
prescription omega-3 fatty acid formulations on
TG, LDL cholesterol, and HDL cholesterol in
patients with hypertriglyceridemia. However, it
should be noted that there is a lack of
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consistency between placebo groups in these
studies; consequently, the results should not be
directly compared.
Several double-blind, placebo-controlled
studies have investigated the efficacy of
OM3EE 4 g/day in patients with severe
hypertriglyceridemia [80–82]. In the two small
studies of patients with very high TG levels
between 500 and 2000 mg/dL (1 with 42
patients and the other with 41 patients) the
mean baseline TG levels were 877 and 801 mg/
dL, respectively [80, 81]. In the third larger
study, 256 patients with lower levels of TG were
enrolled. In these patients with high TG levels
between 200 and 500 mg/dL, the mean baseline
TG level was 282 mg/dL [82]. In all three
studies, OM3EE significantly reduced TG levels
compared with baseline (p B 0.001), with
reductions that ranged from 28% to 45%. The
higher the baseline TG level, the greater the
reduction in TG levels seen [80]. OM3EE also
produced significant increases in HDL
cholesterol over the course of the studies,
ranging from a 4% to 13% increase
(p B 0.023). OM3EE treatment was also
associated with significant increases in LDL-C
cholesterol from 3% to 32% (p B 0.013), which
correlated with the decrease in TG levels.
However, the increase in LDL cholesterol was
attenuated when OM3EEs were given along
with statin therapy.
The efficacy of IPE 2 and 4 g/day has been
investigated in two double-blind,
placebo-controlled, 12-week studies. As with
the OM3EE studies, the mean baseline TG
level differed between the two studies [83, 84].
In the Multi-center, placebo-controlled,
Randomized, double-blINd, 12-week study
with an open-label Extension (MARINE) study,
229 patients with very high TG levels, between
500 and 2000 mg/dL, were randomized to IPE
2 g/day, IPE 4 g/day, or placebo. The baseline
TG levels were 657 mg/dL in the IPE 2 g/day
group and 680 mg/dL in the IPE 4 g/day group
[83]. At 12 weeks, there were significant
placebo-corrected reductions in TG of 20%
with IPE 2 g/day and 33% with 4 g/day
(p B 0.005). IPE 4 g/day also produced a
non-significant placebo-corrected reduction in
LDL cholesterol and HDL cholesterol of 2 and
4%, respectively. IPE 2 g/day produced
non-significant placebo-corrected increases in
LDL cholesterol and HDL cholesterol of 5 and
2%, respectively. In the ANCHOR study the
effects of IPE 2 and 4 g/day were evaluated in
patients with high TG levels C200 and
\500 mg/dL. In this study of 663 patients the
mean baseline TG levels were 254 mg/dL in the
IPE 2 g/day group and 265 mg/dL in the IPE
4 g/day group [84]. IPE 2 g/day and 4 g/day
significantly reduced placebo-corrected TG
levels by 10% and 22%, respectively
(p\0.001). IPE 4 g/day also produced
significant (p\0.01) placebo-corrected
reductions in LDL cholesterol and HDL
cholesterol of 6% and 5%, respectively. IPE
2 g/day produced placebo-corrected reductions
in LDL cholesterol of 4% and HDL cholesterol of
2%; however, these changes were not
statistically significant.
Three doses of OM3CA (2, 3, and 4 g/day)
have been investigated across two double-blind,
parallel-group studies. The EpanoVa fOr
Lowering Very high triglyceridEs (EVOLVE)
study randomized 364 patients with baseline
mean TG levels of 655–728 mg/dL to OM3CA 2,
3, or 4 g/day [85]. At 12 weeks, OM3CA
2–4 g/day significantly reduced TG levels by
26, 26, and 31%, respectively (p\0.01).
OM3CA also produced increases in HDL
cholesterol of 7, 4, and 6%, respectively,
though this did not reach statistical
significance. LDL cholesterol increased by 19%
(p\0.01) at the 2 g/day dose, by 14% (p = NS)
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at the 3 g/day dose, and by 19% (p\0.001) at
the 4 g/day dose. In the Epanova combined
with a Statin in Patients with
hypertriglyceridemIa to Reduce non-HDL
cholesTerol (ESPRIT) study, 627 patients with
baseline mean TG levels of 280–287 mg/dL had
reductions in TG of 15% with OM3CA 2 g/day
and 21% with OM3CA 4 g/day (p\0.001) [86].
The primary endpoint in this trial was change in
non-HDL cholesterol, which was reduced by 4%
(p\0.05) and 7% (p\0.001) with OM3CA
2 g/day and OM3CA 4 g/day, respectively. HDL
cholesterol increased by 3% in both groups, and
LDL cholesterol increased by 5 and 1% with
OM3CA 2 g/day and OM3CA 4 g/day,
respectively.
Figure 2 shows the lipid-lowering effects of
each of these three formulations at their highest
Fig. 2 Change in lipid parameters in patients with high
and very high triglycerides with prescription omega-3 fatty
acid preparations. a OM3EE [64, 65]; b IPE [63];
c OM3CA [66]; Apo B apolipoprotein B, IPE icosapent
ethyl, non-HDL-C non-high-density lipoprotein choles-
terol, LDL-C low-density lipoprotein cholesterol, OM3CA
omega-3 carboxylic acids, NR not reported, OM3EE
omega-3 fatty acid ethyl esters, TG triglycerides, VLDL-C
very low-density lipoprotein cholesterol. Information not
provided for the effect of OM3EE on apo B. Results are
from different studies, as reported in the respective
prescribing information, and cannot be directly compared
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dose available for prescription on TG levels and
various other lipoproteins in patients with TG
C500 mg/dL, as detailed in their respective
prescribing information [63–66]. OM3CA and
OM3EE have both been shown to have
beneficial effects on non-HDL cholesterol and
VLDL cholesterol. OM3CAs are also associated
with a small (6%) increase in apolipoprotein B.
IPE 4 g/day also has positive effects on non-HDL
cholesterol, total cholesterol, VLDL cholesterol,
and apolipoprotein B. However, the reductions
in VLDL cholesterol are not as large with IPE as
they are with OM3CA and OM3EE (20 vs. 35
and 42%, respectively). Although there have
been no comparison studies between the
available prescription omega-3 fatty acid
preparations with regard to their
lipid-lowering effects, in general those
formulations high in DHA appear to provide
greater TG-lowering effects, while those higher
in EPA provide a modest lowering of LDL
cholesterol [78].
There are some differences in bioavailability
between the three prescription omega-3 fatty
acid formulations. IPE and OM3EE both have to
be hydrolyzed by pancreatic lipase before they
can be absorbed [87]. As levels of pancreatic
lipase directly correlate with the type and
amount of lipids consumed, the absorption of
IPE and OM3EE is highly dependent on the fat
content of meals [88]. Given that patients with
hypertriglyceridemia are advised to adhere to
low-fat diets, the absorption of these two
formulations may be adversely affected.
Studies have shown that with low-fat diets,
the bioavailability of EPA and DHA with
OM3CA was four times higher than with
OM3EE [89]. A small pharmacokinetic study of
an investigational omega-3 fatty acid
medication containing predominately EPA and
docosapentaenoic acid (DPA) dosed with
low-fat meals exhibited significantly greater
bioavailability when compared to IPE in
patients with hypertriglyceridemia [90]. Those
formulations such as those containing OM3CA
that do not require pancreatic lipase for
absorption can be taken at any time of the day
and are not restricted to meal times, providing
more flexibility around dosing [89]. The greater
bioavailability afforded by OM3CA
formulations of omega-3 fatty acids may
provide greater reductions in TG at lower
doses compared to other omega-3 fatty acid
formulations. However, to date no
head-to-head comparison studies have been
performed among the different available
omega-3 fatty acid formulations.
Supplements and non-prescription omega-3
fatty acid products are not subject to the same
very strict regulations that prescription
formulations of omega-3 fatty acids are. As a
result, patients may be taking insufficient
amounts of EPA and DHA to have a clinically
significant effect on TG levels. In a recent study
of 32 fish oil supplements by a New Zealand
research team, it was found that there was a
noticeable difference between the claimed
content and the actual content of EPA and
DHA. On average, the supplements were found
to contain just 68% of the claimed content [91].
The researchers also found that there were high
levels of oxidation in the fish oils, with the
majority exceeding the recommended levels of
oxidation markers, which may explain the
gastrointestinal side effects commonly seen
with these over-the-counter supplements.
CONCLUSION
It is estimated that 77 million adults in the US
are at risk of CV disease and pancreatitis because
of elevated TG levels. When TG levels are
[1000 mg/dL, the predominant particles
carrying TG are large chylomicrons, which are
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believed to cause hyperviscosity, leading to
ischemia and acidosis in pancreatic capillaries,
and ultimately pancreatitis. In contrast, when
TG levels are \1000 mg/dL, the predominant
particles carrying TG are VLDL, which are small
enough to penetrate the intima, leading to
injury, inflammation, and atherosclerosis [34].
In individuals with high TG levels between 200
and 499 mg/dL the primary focus for treatment
is lifestyle intervention, with diet and exercise
[5, 10]. Statins may be considered for these
patients based on current cholesterol guidelines
[5, 6]. For patients on a statin who have
persistently high TG levels despite lifestyle
interventions, additional TG-lowering therapy
with prescription omega 3 fatty acids, fibrates,
or niacin may be considered on an individual
basis. When TG levels are C500 mg/dL, and
especially when they are C1000 mg/dL, the
primary treatment strategy is to reduce TG
levels with a TG-lowering drug to reduce the
risk of pancreatitis [5, 10, 12, 13]. High-dose
prescription omega-3 fatty acids have been
shown to reduce TG levels by up to 50% [10].
The three prescription omega-3 fatty acid
formulations currently approved in the US
differ in their content of EPA and DHA. Those
formulations high in DHA provide greater
TG-lowering effects, while those higher in EPA
provided a modest lowering of LDL-C. The
results of two ongoing, large-scale outcomes
studies are awaited to confirm the effect of
prescription omega-3 fatty acids on reducing
CV events.
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